Engineered immune cells target stubborn leukemia in early safety trial
NCT ID NCT06649227
First seen Jan 07, 2026 · Last updated Jun 14, 2026 · Updated 24 times
Summary
This early-phase study tests whether a special type of immune cell (CAR-T) that targets the CD19 protein is safe for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. Only patients whose leukemia cells show CD19 are eligible. The main goal is to check for serious side effects and early death not caused by the cancer itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED ADULT AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Lille
RECRUITINGLille, 59000, France
Contact
Conditions
Explore the condition pages connected to this study.